# Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

> **NCT00535418** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00535418
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2002-07
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535418, "Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00535418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*